Ball T, Edstrom W, Mauch L, et al. Gain of structure and IgE epitopes by eukaryotic expression of the major Timothy grass pollen allergen, Phl p 1. FEBS J 2005;272:217-27. View abstract.
Brecker L, Wicklein D, Moll H, et al. Structural and immunological properties of arabinogalactan polysaccharides from pollen of timothy grass (Phleum pratense L.). Carbohydr Res 2005;340:657-63. View abstract.
Brimnes J, Kildsgaard J, Jacobi H, Lund K. Sublingual immunotherapy reduces allergic symptoms in a mouse model of rhinitis. Clin Exp Allergy 2007;37:488-97. View abstract.
Calderon M, Essendrop M. Specific immunotherapy with high dose SO standardized grass allergen tablets was safe and well tolerated. J Investig Allergol Clin Immunol 2006;16:338-44. View abstract.
Casanovas M, Sastre J, Fernández-Nieto M, et al. Double-blind study of tolerability and antibody production of unmodified and chemically modified allergen vaccines of Phleum pratense. Clin Exp Allergy 2005;35:1377-83. View abstract.
Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006;61:185-90. View abstract.
Hannan JM, Marenah L, Ali L, et al. Insulin secretory actions of extracts of Asparagus racemosus root in perfused pancreas, isolated islets and clonal pancreatic beta-cells. J Endocrinol 2007;192:159-68. View abstract.
Kaur A, Skoner D, Ibrahim J, et al. Effect of grass sublingual tablet immunotherapy is similar in children and adults: a Bayesian approach to design pediatric sublingual immunotherapy trials. J Allergy Clin Immunol. 2018 May; 141(5):1744-1749. View abstract.
Kildsgaard J, Brimnes J, Jacobi H, Lund K. Sublingual immunotherapy in sensitized mice. Ann Allergy Asthma Immunol 2007;98:366-72. View abstract.
Malling HJ, Lund L, Ipsen H, Poulsen L. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Investig Allergol Clin Immunol 2006;16:162-8. View abstract.
Maloney J, Bernstein DI, Nelson H, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large, randomized controlled trial. Ann Allergy Asthma Immunol. 2014 Feb;112(2):146-153.e2. View abstract.
Motta A, Peltre G, Dormans JA, et al. Phleum pratense pollen starch granules induce humoral and cell-mediated immune responses in a rat model of allergy. Clin Exp Allergy 2004;34:310-4. View abstract.
Motta AC, Dormans JA, Peltre G, et al. Intratracheal instillation of cytoplasmic granules from Phleum pratense pollen induces IgE- and cell-mediated responses in the Brown Norway rat. Int Arch Allergy Immunol 2004;135:24-9. View abstract.
Niggemann B, Jacobsen L, Dreborg S, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006;61:855-9. View abstract.
Pfaar O, Hohlfeld JM, Al-Kadah B, et al. Dose-response relationship of a new Timothy grass pollen allergoid in comparison with a 6-grass pollen allergoid. Clin Exp Allergy. 2017 Nov;47(11):1445-1455. View abstract.
Rak S, Yang WH, Pedersen MR, Durham SR. Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual Life Res 2007;16:191-201. View abstract.
Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 2006;117:263-8. View abstract.
Rondón C, Blanca-López N, Campo P, et al. Specific immunotherapy in local allergic rhinitis: a randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy. Allergy. 2018 Apr;73(4):905-15. View abstract.
Rossi RE, Monasterolo G, Coco G, et al. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Vaccine 2007;25:957-64. View abstract.
Sola J, da Silva Ferreira JA, Dionicio Elera J, et al. Timothy grass pollen therapeutic vaccine: optimal dose for subcutaneous immunotherapy. Immunotherapy. 2016;8(3):251-63. View abstract.
Sola J, Sánchez V, Landeta A, Madariaga B, Martínez A, Álvarez-Cuesta E. A Phase I clinical trial with subcutaneous immunotherapy vaccine of Timothy grass pollen extract according to EMA guidelines. Immunotherapy. 2015;7(4):343-52. View abstract.